Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 6;176(1):124–136. doi: 10.1093/toxsci/kfaa049

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Figure 6. — Effects of 7-day IGF-1 and dexamethasone application on myobundle biomarker release. Cumulative biomarker release profiles and quantifications of total release normalized to drug-free control during 7 days of IGF-1 and dexamethasone application, shown for (A, B) CK, (C, D) LDH, (E, F) CKm, (G, H) Fabp3, (I, J) sTnI, and (K, L) cTnT release after 7 days. *p < .01 from CTL. Quantifications performed from n = 8 myobundles per donor, n = 2 technical replicate, from N = 2 donors. CTL, drug-free control; IGF 0.1, 0.1 mg/ml IGF-1; IGF 0.5, 0.5 mg/ml IGF-1; Dex 1, 1 μM dexamethasone; Dex 25, 25 μM dexamethasone; BLLOD, below lower limit of detection.